Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)

NCT07304089 is registered in ClinicalTrials.gov with Vima Therapeutics as lead sponsor.

NCT NCT07304089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07304089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)
Lead sponsor
Vima Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
February 5, 2026
Completion date
May 31, 2027
Enrollment
100 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

dystonia